Maiwei Biotech (688062.SH): 9MW1911 injection clinical trial application obtained FDA approval

Zhitongcaijing · 1d ago

Zhitong Finance App News, Maiwei Biotech (688062.SH) issued an announcement. Recently, the company received the “Study May Proceed Notification” (Study May Proceed Notification) issued by the US Food and Drug Administration (FDA), and the 9MW1911 injection clinical trial application was officially approved by the FDA.

9MW1911 is an innovative monoclonal antibody independently developed based on an efficient B-lymphocyte screening platform. It is a class 1 of therapeutic biological products and can bind to ST2 receptors with high affinity, thereby blocking the IL33/ST2 signaling pathway.